Total trial protocols, including the statistical analysis plans, can be found at NEJM.org. All the authors had access to all data and attest to the precision and completeness of the data and for the fidelity of the trials to the final protocols; all the authors were mixed up in interpretation of the info and in the writing and editing of the manuscript and made a decision to submit the manuscript for publication. Editorial assistance was provided by International Meetings and Technology. Representatives of Boehringer Ingelheim designed and conducted the trial with the 1st author and gathered and analyzed the data. Funding for the trials and editorial assistance was provided by Boehringer Ingelheim and Pfizer. Trial and Concomitant Medications Individuals were assigned to self-administer two puffs of either 2 randomly.e.The scholarly study findings, which represent yet another five months of follow-up, were shown at the 2011 CTRC-AACR San Antonio Breast Malignancy Symposium , abstract #S3-7[1]. Simultaneously, initial outcomes of BOLERO-2 were published today in The New England Journal of Medicine and were initial presented at the 2011 European Multidisciplinary Cancer Congress [2]. These data provide longer-term evidence of the benefit of adding everolimus to hormonal therapy in patients whose disease progressed while on or following preliminary hormonal treatment, representing a significant paradigm change in the management of ER+HER2 – breast cancers, stated Gabriel Hortobagyi, MD, Chair of Breasts Medical Oncology, University of Texas MD Anderson Cancers Center and lead study author.